Are you getting the best rate from your broker?
Compare your broker's rates now to find out if you can save money

Choose your broker below
Thank you for selecting your broker
We are redirecting you to the Broker Center now
Welcome to Dividend.com. Please help us personalize your experience.

Select the one that best describes you
Thank you for your submission, we hope you enjoy your experience

REIT With 89 Consecutive Dividend Payments Makes Best Dividend Stocks List

Dividend logo

The major pharmaceutical companies are facing quite a predicament. Billions of dollars worth of patent-protected drugs have already gone or are preparing to go generic over the next few years. Dubbed the “patent cliff”, the loss of these blockbusters and other major money-making drugs for the largest pharmaceutical companies is enough to make any investor cringe. For dividend investors, it’s especially troublesome as some of these drugs have been the driving force behind Big Pharma’s status as dividend safe havens.

Rather than resignedly driving over the cliff, Big Pharma has at least begun to pump the brakes and look for alternatives. As a result, Big Pharma has found itself diving head first into biotech manufacturers and their lucrative cures for rare diseases.

Except, it turns out that biotech may not be the panacea they hoped for. Regulation and public scorn could crimp the ability of the biotechs – and correspondingly Big Pharma – to charge an arm and a leg for the medications.

To read the Full Story, Go Premium or Log In

Popular Articles

Best Online Brokers

At Dividend.com a large portion of our readership is of a discerning, self-directed nature. As...


Ford Motor Co. Leads 50 Stocks Going Ex-Dividend Next Week

There are 50 stocks going ex-dividend next week, starting Monday, October 24. For income...

Premium Shutterstock 200290379

It's 10 p.m. Do You Know Where Your Dividend Accounts Are?

That headline – for those not old enough to remember – is a take-off of a public service...